West Pharmaceutical Services (WST) Equity Income (2009 - 2026)

West Pharmaceutical Services has disclosed Equity Income across 18 years of filings, most recently posting $3.4 million for Q1 2026.

• Equity Income for Q1 2026 came in at $3.4 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.4 million (up 4.35% YoY), and the FY2025 annual result was $14.4 million, down 2.04% from the prior year.
• Equity Income came in at $3.4 million for Q1 2026 at West Pharmaceutical Services, down from $3.9 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $7.2 million in Q1 2022 to a low of $2.0 million in Q4 2024.
• The 5-year median for Equity Income is $3.9 million (2024), against an average of $4.2 million.
• Peak annual rise in Equity Income reached 95.0% in 2025, while the deepest fall reached 46.15% in 2025.
• West Pharmaceutical Services' Equity Income stood at $3.2 million in 2022, then rose by 3.12% to $3.3 million in 2023, then slumped by 39.39% to $2.0 million in 2024, then surged by 95.0% to $3.9 million in 2025, then dropped by 12.82% to $3.4 million in 2026.
• The last three Equity Income figures came in at $3.4 million (Q1 2026), $3.9 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.